Less-Threatening Omicron Lowers Covid Vaccine Sales Estimate
- Airfinity cuts 2022 shot revenue projection 28% to $85 billion
- Sales still expected to rise almost 30% from last year
Workers transport boxes of Johnson & Johnson Covid-19 vaccines from the production line in Gqeberha, South Africa.
Photographer: Waldo Swiegers/BloombergThis article is for subscribers only.
Evidence that omicron causes less-severe disease than earlier Covid-19 variants will likely blunt growth in vaccine sales this year as wealthier countries rein in purchases, according to Airfinity Ltd.
Sales of Covid vaccines, excluding those from China and India, will increase to about $85 billion in 2022, down about 28% from an earlier estimate of $118 billion, London-based Airfinity said Friday. The revision was also due to lower prices paid by poorer nations that are finally obtaining shots, the analytics firm said.